TORONTO, Ontario, June 10, 2021 – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony…

Vancouver, B.C., June 8, 2021 – 1169082 B.C. Ltd. (the “Company”) and Awakn Life Sciences Inc. (“Awakn”), are pleased to announce the closing of the previously announced brokered private placement…

Vancouver, British Columbia–(Newsfile Corp. – May 17, 2021) – 1169082 B.C. Ltd. (the “Company”) is pleased to announce that it has entered into a definitive binding amalgamation agreement dated May 13, 2021…

Defining clear development pathway for next generation of psychedelic medicines to treat addiction Awakn announces today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline…

Awakn announces the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the company’s Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent…

First project to use advanced analytics to explore identity shifts in alcohol addiction Awakn launches ‘Awakn Digital’, a new unit focused on using advanced analytics to improve the effectiveness of…

Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and…

Awakn intends to run a Phase III trial for ‘Ketamine-Assisted Psychotherapy for Alcohol Use Disorder’ Awakn announced today an exclusive license to use and deliver the ‘Ketamine in the Reduction…

Awakn announces today the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…

Today Awakn announces the appointment of James Collins as Chief Operating Officer, effective January 2021. Collins joins from Accenture Strategy where he was a Managing Director (London) for several years,…

Awakn announces today the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for…

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment Awakn announces today the selection of contract research organization (‘CRO’),…